ArticlePediatric cardiology2026
Necrotizing Enterocolitis in Infants with Hybrid Stage 1 Palliation is Common and Difficult to Predict.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hybrid stage 1 palliation (HS1P) is performed at many centers for patients with single ventricle heart disease or complex biventricular heart disease and high-risk features. Necrotizing enterocolitis (NEC) is common in these infants, although specific risk factors have not been identified to predict those who will develop NEC. A single-center retrospective chart review of 105 infants who underwent HS1P at < 30 days of age was performed. Clinical, procedural, and echocardiographic features at HS1P and prior to NEC episodes were collected. Hypoplastic left heart syndrome accounted for 54.3% of patients. HS1P was performed at a median of 5 days of life, with 78.1% having a ductal stent placed and 35.2% having an atrial septal intervention. Overall, 56 infants (53.3%) developed NEC prior to their next surgery. Stage 1 NEC occurred in 42 infants (75.0%), with stage 2/3 NEC occurring in 14 infants (25.0%). Having three or more risk factors leading to the decision to undergo HS1P was associated with development of NEC (p = 0.01). Infants with stage 2/3 NEC were more likely to receive a general surgery consult (100% vs. 33.3%), had longer NPO times (median 7 vs. 3 days), longer antibiotic course (median 7 vs. 4 days), longer hospital length of stay (median 73.5 vs. 43 days), and were less likely to be discharged home prior to next surgical intervention (28.6% vs. 47.6%) than those with stage 1 NEC (all p < 0.05). Infants undergoing HS1P are at high risk for NEC with a significant impact on patients' clinical courses.
Indexed as
Identifiers
42570016What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.